The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma

• Main Authors: Haibo Zhu, Yazhou Miao, Yutao Shen, Jing Guo, Weiyan Xie, Sida Zhao, Wei Dong, Yazhuo Zhang, Chuzhong Li
• Format: Article
• Language: English
• Published: BMC 2019-10-01
• Series: Journal of Translational Medicine
• Subjects: Clinical characteristics; Molecular mechanism; MEN1; PAM; mTOR
• Online Access: http://link.springer.com/article/10.1186/s12967-019-2103-0

Abstract Background Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. Methods We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray. Results Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM. Conclusions MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future.